Claims for Patent: 9,869,677

Summary for Patent: 9,869,677

Title:	Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
Abstract:	Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
Inventor(s):	Nixon; Andrew B. (Durham, NC), Hurwitz; Herbert I. (Durham, NC), Pang; Herbert (Durham, NC), Starr; Mark D. (Durham, NC)
Assignee:	Duke University (Durham, NC)
Application Number:	15/001,419
Patent Claims:	1. A method of predicting responsiveness of pancreatic cancer in a subject to a cancer therapy including a VEGF targeting agent comprising: obtaining a sample from the subject; measuring a protein expression level of VEGF-C and GROa in the sample from the subject; generating a comparison of the protein expression level of VEGF-C and GROa in the sample to a reference level of the biomarker; and using said comparison to predict the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent, wherein low levels of VEGF-C in combination with high levels of GROa are predictive of lack of responsiveness of the cancer to treatment including a VEGF targeting agent, wherein the prediction indicates unfavorability of including a VEGF targeting agent in the cancer therapy when the protein expression level of VEGF-C is less than 575 pg/mL and the protein expression level of GROa is more than 70 pg/mL, and wherein the prediction indicates a VEGF targeting agent should be included in the cancer therapy when the protein expression level of VEGF-C is more than 575 pg/mL and the protein expression level of GROa is less than 70 pg/mL. 2. The method of claim 1, further comprising treating the subject with the VEGF targeting agent if the cancer is predicted to be responsive to the VEGF targeting agent. 3. The method of claim 1, wherein lack of responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects not treated with a VEGF targeting agent. 4. The method of claim 1, wherein the subject is human. 5. The method of claim 4, wherein the subject is a human patient diagnosed with cancer or undergoing, or about to undergo, a cancer treatment regimen. 6. The method of claim 1, wherein the reference level is determined by analysis of a set of samples from cancer patients treated with cancer therapies including or excluding a VEGF targeting agent with known outcomes. 7. The method of claim 1, wherein the VEGF targeting agent is bevacizumab. 8. The method of claim 1, wherein the cancer therapy includes a nucleotide analog or other inhibitor of DNA synthesis and repair. 9. The method of claim 8, wherein the inhibitor is gemcitabine. 10. The method of claim 1, wherein the sample is blood, plasma, serum, or urine. 11. The method of claim 1, wherein the protein expression level is determined by a method selected from ELISA, immunofluorescence, FACS analysis, Western blot, magnetic immunoassays, and antibody-based microarrays. 12. A method of treating pancreatic cancer in a subject comprising: administering a VEGF targeting agent to the subject if a sample from the subject has a protein expression level of VEGF-C that is greater than 575 pg/mL and the protein expression level of GROa is less than 70 pg/mL. 13. The method of claim 12, wherein the sample is blood, plasma, serum, or urine. 14. The method of claim 12, wherein the protein expression level is determined by a method selected from the group consisting of ELISA, immunofluorescence, FACS analysis, Western blot, magnetic immunoassays, antibody-based microarrays. 15. The method of claim 12, wherein the VEGF targeting agent is bevacizumab.

Details for Patent 9,869,677

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2031-05-05